These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39092765)

  • 1. Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy.
    Ma X; Zhou Y; Li R; Ding X; Li D; Pan T; Zhang F; Li W
    Mol Carcinog; 2024 Oct; 63(10):1866-1873. PubMed ID: 39092765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP and the Hippo pathway in cholangiocarcinoma.
    Sugihara T; Isomoto H; Gores G; Smoot R
    J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
    Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.
    Galli GG; Carrara M; Yuan WC; Valdes-Quezada C; Gurung B; Pepe-Mooney B; Zhang T; Geeven G; Gray NS; de Laat W; Calogero RA; Camargo FD
    Mol Cell; 2015 Oct; 60(2):328-37. PubMed ID: 26439301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the Hippo-YAP/TAZ Pathway in Epithelioid Hemangioendothelioma and its Potential as a Therapeutic Target.
    Suto H
    Anticancer Res; 2024 Oct; 44(10):4147-4153. PubMed ID: 39348982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
    Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
    Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
    Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
    Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of Hippo kinase signalling in human hepatic malignancies.
    Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
    Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m
    Wu J; Yi T; Zhuo C; Wang D; Zhang M; Hu R; Wu D; Hou G; Xing Y
    J Cell Physiol; 2024 May; 239(5):e31220. PubMed ID: 38372068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway.
    Sun Y; Jiang T; Jia Y; Zou J; Wang X; Gu W
    Cell Cycle; 2019 Oct; 18(19):2509-2523. PubMed ID: 31397203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
    Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
    Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies.
    Werneburg N; Gores GJ; Smoot RL
    Gene Expr; 2020 Jun; 20(1):67-74. PubMed ID: 31253203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma.
    Sugimachi K; Nishio M; Aishima S; Kuroda Y; Iguchi T; Komatsu H; Hirata H; Sakimura S; Eguchi H; Bekki Y; Takenaka K; Maehara Y; Suzuki A; Mimori K
    Oncology; 2017; 93(1):67-74. PubMed ID: 28448997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.
    Vargas RE; Duong VT; Han H; Ta AP; Chen Y; Zhao S; Yang B; Seo G; Chuc K; Oh S; El Ali A; Razorenova OV; Chen J; Luo R; Li X; Wang W
    EMBO J; 2020 Jan; 39(1):e102406. PubMed ID: 31782549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EP300 promotes lung cancer cell proliferation by regulating the oncogenic transcription of Hippo-YAP signaling pathway.
    Li S; Shi J; Wang L; Zhang D; Zhang H
    Biochem Biophys Res Commun; 2024 Jan; 692():149330. PubMed ID: 38048728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomolecular condensates: hubs of Hippo-YAP/TAZ signaling in cancer.
    Kiang KM; Ahad L; Zhong X; Lu QR
    Trends Cell Biol; 2024 Jul; 34(7):566-577. PubMed ID: 38806345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.